Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elastase enteric tablets contain elastase, a serine protease typically extracted from porcine pancreas. The enteric coating is designed to protect the enzyme from degradation by gastric acid, ensuring its release in the small intestine. Clinically, it is primarily indicated for the treatment of hyperlipidemia and the prevention and treatment of atherosclerosis. The enzyme works by degrading elastin in the arterial wall and influencing lipid metabolism, which leads to a reduction in serum cholesterol and triglyceride levels while improving arterial elasticity and vascular compliance. InnoShengKang (Changzhou Qianhong Bio-pharma) is a major developer and manufacturer of this approved pharmaceutical product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on elastase.